



15<sup>th</sup> December 2017

The Secretary,  
Bombay Stock Exchange Limited,  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai 400 001

The Secretary,  
The National Stock Exchange of India Limited  
Exchange Plaza, 5<sup>th</sup> Floor,  
Plot No. C/1, G Block,  
Bandra-Kurla Complex,  
Bandra East,  
Mumbai 400 050

**Press Release - Sanofi India Limited appoints N. Rajaram as Managing Director**

Dear Sir,

We enclose herewith a copy of press release on the above subject, contents of which are self-explanatory for your information and records.

Thanking you,

Yours sincerely,  
SANOFI INDIA LIMITED

  
GIRISH TEKCHANDANI  
COMPANY SECRETARY



## Sanofi India Limited appoints N. Rajaram as Managing Director

*- Dr. Shailesh Ayyangar takes up regional role within Sanofi Asia Region -*

**Mumbai, India – December 15, 2017** - Sanofi India Limited (SIL) announced the elevation of **N. Rajaram** as the Managing Director of the Company, with effect from 1<sup>st</sup> January, 2018. His appointment was approved by the Sanofi India Board of Directors earlier today. N. Rajaram joined Sanofi India in February 2014 and was appointed as Whole Time Director in October 2015. Under his leadership, the Company has doubled the size of its diabetes business and established a foothold in the consumer healthcare sector, while significantly transforming its market operations.

Rajaram brings with him diverse experience of nearly two decades in the FMCG industry with Hindustan Unilever, and in the telecom industry with Airtel. Rajaram holds a bachelor's degree in Engineering from the Birla Institute of Technology & Science (BITS), Pilani, India and an MBA in International Business from the Indian Institute of Foreign Trade (IIFT), New Delhi. **He is also an alumnus of the Advanced Managed Program of the Harvard Business School.**

N. Rajaram succeeds **Dr. Shailesh Ayyangar** who has been the Managing Director of Sanofi India Limited for over 12 years. Dr. Ayyangar will take up a new role in the Sanofi Asia region effective January 1st, 2018. He will also continue as a Non-Executive Director on the Board of Sanofi India Limited.

Speaking about the transition, Dr. Ayyangar said, *"I am truly grateful for the trust and confidence reposed on me over the years, by Sanofi India Limited's shareholders, and other stakeholders including our employees and the senior leadership within Sanofi. It has been a real privilege to serve the Company and the country over a long period."* He further added that *"While I am looking forward to taking on a new position in Sanofi Asia region, I am delighted to welcome N. Rajaram as the new Managing Director of SIL. This transition has been planned well in advance and I am very confident that under his leadership, SIL will scale greater heights of performance and continue to serve the patients of our country"*.

Speaking on the occasion, N. Rajaram said, *"Sanofi is a great global organization, which is focused on delivering transformational outcomes for patients based on scientific innovation and improved access to healthcare solutions. Our people have a contagious commitment and passion to empower the lives of the millions of patients we serve, making Sanofi an exciting and purposeful place to work. I'm thrilled to be part of this journey and hope to steer the Company through its next phase of growth"*.

### About Sanofi

Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.

With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.



**Sanofi Forward-Looking Statements**

*This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi's ability to benefit from external growth opportunities and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic conditions, the impact of cost containment initiatives and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2016. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.*

---

**Contacts:**

**Media Relations**

Aparna Thomas

Tel. : +91 (22) 2803 2169

[aparna.thomas@sanofi.com](mailto:aparna.thomas@sanofi.com)